CliffBio
small molecule

TIVICAY PD

DOLUTEGRAVIR SODIUM

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyViiV Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameTIVICAY PD
Active ingredientDOLUTEGRAVIR SODIUM
StrengthEQ 5MG BASE
Dosage formTABLET, FOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2020
Marketing statusRX

Listed patents

PatentExpiresType
9242986*PEDJune 2030—
9242986December 2029substance, product
8129385*PEDApril 2028—
8129385October 2027substance, product

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TIVICAY PD patent cliff — loss of exclusivity June 2030 | CliffBio